Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

Keytruda hits survival targets in first-line kidney cancer

Keytruda hits survival targets in first-line kidney cancer

Bristol-Myers Squibb’s cancer immunotherapy pairing of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) was approved earlier this year as first-line treatment for RCC, but only

Cancer disruptor F Star names next CEO

Cancer disruptor F Star names next CEO The company has deals with the likes of Bristol-Myers Squibb, Merck KGaA and AbbVie.

BMS finds a new immunotherapy partner with $12m Compugen deal

BMS finds a new immunotherapy partner with $12m Compugen deal Combination with novel antibody targeting PVRIG pathway. Bristol Myers Squibb is continuing its tireless search for the perfect immunotherapy combination, today announcing a new $12m deal with Compugen. ... The collaboration is also designed to address

BMS finds a new immunotherapy partner with $12m Compugen deal

BMS finds a new immunotherapy partner with $12m Compugen deal BMS finds a new immunotherapy partner with $12m Compugen deal. Bristol Myers Squibb is continuing its tireless search for the perfect immunotherapy combination, today announcing a new $12m deal with Compugen. ... The collaboration is also designed to

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics